genOway, the European market leader in transgenesis, takes over commercial activities for IngenKO Pty Ltd following the Australian company's closure. This confirms genOway's leading position in the market and contributes to the worldwide expansion of the company's activities, states a company release.

IngenKO was set up in June 2001 as a spin-off company of Monash University, a renowned academic institute and a leader in stem cell research. The company gained 4 years experience as a commercial supplier of gene-targeted mice on a service-fee basis to customers in the academic, pharmaceutical, biotechnology and medical research communities in Australia, the US, Europe, Japan and Asia. IngenKO was one of the major players in this very competitive market, said the release.

Prior to IngenKO's closing, genOway was contacted to facilitate the transfer of a number of projects. "With a high production capacity, and high quality services, genOway was the obvious choice to complete the IngenKO's projects. IngenKO's customers welcomed this transfer of supplier, as they were reassured by genOway's expertise and market position," said Dr Rocco Iannello, business development manager, Monash Institute of Medical Research, Monash University.

Based in Lyons, France and Hamburg, Germany, genOway is the European market leader in transgenesis. genOway's mission is to provide pharmaceutical and academic research institutes with tailor-made genetically modified animal models for gene validation, drug screening, pharmacological and toxicological studies.